Business
Schrödinger to Present New Data for SGR-1505 and SGR-2921 at American Society of Hematology 2023 Annual Meeting
NEW YORK--(BUSINESS WIRE)-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are
About this update from Schrodinger, Inc.
[{"type":"text","content":" NEW YORK--(BUSINESS WIRE)--\nSchrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that new data on SGR-1505, its investigational MALT1 inhibitor, and SGR-2921, its investigational CDC7 inhibitor, will be presented during a poster session at the American Society of Hematology (ASH) 65th Annual Meeting taking place virtually and in San Diego, California, December 9-12, 2023.\n\n\nPresentation of SGR-1505 data will include further characterization in preclinical oncology models as well as preliminary clinical biomarker information from the Phase 1 study in healthy subjects, which is nearing completion. The data support continued development of SGR-1505 as a potential therapy for patients with advanced B-cell malignancies, and a Phase 1 dose-escalation study in this patient population is ongoing.\n\n\nAdditionally, data will be presented for SGR-2921 demonstrating strong anti-leukemic activity in preclinical models of acute myeloid leukemia (AML) representing difficult-to-treat disease. CDC7 is a cell cycle kinase in the DNA damage-response pathway and has emerged as a promising therapeutic target in oncology, including for the treatment of AML. Schrödinger recently initiated a Phase 1 dose-escalation study of SGR-2921 designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and recommended dose of SGR-2921 in patients with AML or myelodysplastic syndrome.\n\n\nDetails of the data presentations are as follows:\n\n\nTitle: SGR-1505 Is a Potent MALT1 Protease Inhibitor with a Potential Best-in-Class Profile\nAbstract number: 2997\nDate & time: Sunday, December 10, 6:00 p.m. - 8:00 p.m. PDT\nLocation: San Diego Convention Center, Halls G-H\n\n\nTitle: SGR-2921, a Potent CDC7 Inhibitor, Demonstrates Significant Anti-Leukemic Responses in Patient-Derived AML Models Representing Difficult-to-Treat Disease\nAbstract number: 2801\nDate & time: Sunday, December 10, 6:00 p.m. - 8:00 p.m. PDT\nLocation: San Diego Convention Center, Halls G-H\n\n\nAdditionally, the following clinical trial-in–progress posters will be presented for both SGR-1505 and SGR-2921:\n\n\nTitle: A Phase 1, Open-Label, Multicenter, Dose-Escalation Study of SGR-1505 As Monotherapy in Subjects with Mature B-Cell Malignancies\nAbstract number: 3102\nDate & time:...